CIK 0001434316
- Non-accelerated filer
- Smaller reporting company
FATE THERAPEUTICS INC
Sign in to watch- Ticker
- FATE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 651311552
- Phone
- +1 858-875-1803
- Business address
- 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA, 92131
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $13,525
- in 1 filing
Net −$13,525. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-03-14 | Valamehr Bahram Chief R&D Officer | Sale | −3,067 | $31.66 | $97K | 185,089 |
| 2022-03-14 | Valamehr Bahram Chief R&D Officer | Sale | −2,195 | $32.49 | $71K | 182,894 |
| 2022-03-14 | Valamehr Bahram Chief R&D Officer | Sale | −2,960 | $33.30 | $99K | 179,934 |
| 2022-03-14 | Valamehr Bahram Chief R&D Officer | Sale | −100 | $34.04 | $3K | 179,834 |
| 2022-03-14 | Valamehr Bahram Chief R&D Officer | Option exercise · Stock Option (Right to Buy) | −25,000 | 36,156 | ||
| 2022-03-10 | MENDLEIN JOHN Director | Option exercise | +31,562 | $1.63 | $51K | 191,017 |
| 2022-03-10 | MENDLEIN JOHN Director | Sale | −19,493 | $34.73 | $677K | 171,524 |
| 2022-03-10 | MENDLEIN JOHN Director | Sale | −12,069 | $35.48 | $428K | 159,455 |
| 2022-03-10 | MENDLEIN JOHN Director | Option exercise · Stock Option (Right to Buy) | −31,562 | 0 | ||
| 2022-01-25 | Valamehr Bahram See Remarks | Grant or award | +33,302 | 179,834 | ||
| 2022-01-25 | Valamehr Bahram See Remarks | Grant or award · Stock Option (Right to Buy) | +53,058 | 53,058 | ||
| 2022-01-25 | Chu Yu-Waye Chief Medical Officer | Grant or award | +33,302 | 155,095 | ||
| 2022-01-25 | Chu Yu-Waye Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +53,058 | 53,058 | ||
| 2022-01-25 | Plavsic Mark Chief Technical Officer | Grant or award | +33,302 | 130,842 | ||
| 2022-01-25 | Plavsic Mark Chief Technical Officer | Grant or award · Stock Option (Right to Buy) | +53,058 | 53,058 | ||
| 2022-01-25 | Dulac Edward J III Chief Financial Officer | Grant or award | +33,302 | 141,936 | ||
| 2022-01-25 | Dulac Edward J III Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +53,058 | 53,058 | ||
| 2022-01-25 | Wolchko J Scott President and CEO | Grant or award · Stock Option (Right to Buy) | +289,403 | 289,403 | ||
| 2022-01-25 | TAHL CINDY See Remarks | Grant or award | +33,302 | 189,151 | ||
| 2022-01-25 | TAHL CINDY See Remarks | Grant or award · Stock Option (Right to Buy) | +53,058 | 53,058 |
Page 12 of 26 · 503 trades